Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Breast cancer recurrence and metastasis significantly worsen patient prognosis.
• MicroRNAs (miRNAs) are increasingly recognized for their critical roles in breast cancer development and metastasis.
• miR-34a is notably downregulated in breast cancer cells and tissues, suggesting its potential as a therapeutic target.

Purpose of the Study:

• To investigate the therapeutic potential of miR-34a for breast cancer treatment.
• To develop and evaluate a targeted miR-34a expression system (T-VISA-miR-34a) for its antitumor effects, efficacy, mechanism, and safety.

Main Methods:

• Designed a targeted miR-34a expression plasmid (T-VISA-miR-34a) utilizing the T-VISA system.
• Assessed in vitro effects on breast cancer cell growth, migration, and invasion.
• Evaluated in vivo efficacy and systemic toxicity in an orthotopic mouse model using T-VISA-miR-34a complexed with nanoparticles.

Main Results:

• T-VISA-miR-34a achieved robust and persistent miR-34a expression.
• In vitro studies showed significant suppression of breast cancer cell growth, migration, and invasion via downregulation of E2F3, CD44, and SIRT1.
• In vivo, T-VISA-miR-34a nanoparticles markedly inhibited tumor growth and prolonged survival without inducing systemic toxicity.

Conclusions:

• T-VISA-miR-34a effectively induces specific overexpression of miR-34a in breast cancer cells.
• This approach demonstrates potent antitumor effects both in vitro and in vivo.
• T-VISA-miR-34a represents a promising, specific, and safe targeted therapeutic strategy for breast cancer.